Page 2 - Anjali Singh

Jaguar Land Rover cyberattack hit TaMo PV Q2 showing; FY26 outlook cut

One-time gain lifts consolidated profit; company cuts FY26 outlook

Record festival sales, GST cuts help Eicher Motors log 24% profit rise

Revenue hits all-time high, GST cut boosts demand for sub-350cc bikes; seeks uniform 18% GST across all motorcycle segments to boost domestic demand and global competitiveness

Moving India: The ₹2-trillion connectivity projects bet to unclog Mumbai

Metro sprawl, coastal links, and a fading bus fleet - Maximum City's biggest transport makeover yet is racing time, rain, and red tape to keep it moving

Tata Motors' CV arm lists on BSE, seeks clean mobility, tech-led growth

Company working on electrification, hydrogen-powered trucks, new energy buses

Yamaha enters India's EV market, to roll out 10 new models by end-2026

Yamaha expects its first EVs to hit showrooms by the first quarter of FY26 (January-March), once network readiness is complete

Bharat Forge Q2 profit rises 23% on strong domestic, defence gains

Bharat Forge Q2 profit rises 23% to ₹299 crore; defence, industrial growth offset North America slowdown. Shares jump 5.6% after results

Festival cheer, tax cuts fuelled strong commercial vehicle recovery in Oct

India's commercial vehicle market logged its best post-pandemic retail growth in over two years as GST cuts, freight recovery, and festive buying lifted demand across segments

Shailesh Chandra becomes first Indian to head global auto body OICA

Chandra becomes the first Indian to head OICA, marking a significant milestone for India's presence in global automotive decision-making

SUVs, rural growth, premiumisation to keep PV sales in fast lane in 2026

From the Maruti WagonR Electric to the Tesla Model 3, 2026 will be a landmark year for India's auto industry, led by SUVs, hybrids, and EVs amid GST reforms and rising rural demand

Cipla Q2 results: Profit rises 4%, revenue hits record ₹7,589 crore

The company bets on Eli Lilly tie-up for GLP-1 drug, biosimilars expansion; reaffirms $1 billion US revenue goal

Lupin Digital Health unveils VitaLyfe, AI-driven heart wellness app

The AI-powered platform aims to help working professionals manage cardiometabolic risks through heart-age tracking, personalised nutrition, and guided exercise

Hero MotoCorp rides into France with Hunk 440 to boost global footprint

India's largest two-wheeler maker marks its French debut through a partnership with GD France, expanding its European presence after Italy, Spain, and the UK

Max Healthcare's 10,000-bed expansion built with zero debt: MD Abhay Soi

Max Healthcare's ₹6,000 crore plan to add 10,000 beds over four years will be fully funded through internal accruals, says CMD Abhay Soi, outlining a strategy for growth without margin dilution

Harman invests ₹345 crore to expand Pune plant for connected vehicles

The Samsung-owned firm to ramp up production capacity by 50%, adding new SMT lines and next-gen telematics systems for global and Indian automotive clients

JK Tyre & Industries Q2 profit jumps 64% on rural demand, GST boost

JK Tyre continues to supply the US from its Mexico base while awaiting outcomes from ongoing trade negotiations

Domestic demand, GST cut to drive 8-10% growth for fleet firms: Crisil

Fleet operators' revenues to rise 8-10% in FY26 on strong domestic demand, infrastructure push, and GST cut, even as higher truck costs lift expenses

GST cut, festival demand fuel two-wheeler sales boom in October

Hero, Honda lead record monthly sales as consumers snap up bikes

Dr Reddy's Q2 net profit up 14% despite slump in North America biz

For H1FY26, profit after tax rose 8 per cent Y-o-Y and revenue grew 11 per cent, led by branded markets and contributions from the Nicotine Replacement Therapy (NRT) portfolio

Biocon Biologics gets Health Canada approval for Yesintek, Yesintek I.V.

The approval of Yesintek and Yesintek I.V., biosimilars to Stelara, strengthens Biocon Biologics' presence in North America and expands its immunology portfolio

Lilly and Cipla to market tirzepatide in India under new brand Yurpeak

The Lilly-Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and obesity care across urban and semi-urban markets